BCG vaccine extensively used even in countries where efficacy against pulmonary tuberculosis is negligible. A number of possible reasons for the variable efficacy of BCG in different countries have been proposed. None have been proven, some have been disproved, and none can explain the lack of efficacy in both low-TB burden countries (US) and high-TB burden countries (India). The reasons for variable efficacy have been discussed at length in a WHO document on BCG. BCG has protective effects against some non-tuberculosis mycobacteria. BCG has been one of the most successful immunotherapies. BCG vaccine has been the "standard of care for patients with
BCG disease outbreak in Finland in the 2000s a disease which in scientific peer-reviewed articles (case descriptions) have been mistakenly first made, and afterward have been noticed to be disseminated BCG infections. One death with a causal link considered established by the adverse event monitoring agency was vaccinated with pre-August 2002 vaccine (Evans), while the three other registered deaths were with the new post-August 2002 vaccine (BCG Vaccine SSI). Officially, vaccination policy is divided to many governmental organizations like the National Agency for Medicines, National Public Health Institute, the National Authority for Medicolegal Affairs, National Research and Development Centre for Welfare and Health (STAKES), the Health Department etc.